Related Experiment Videos
Sepsis and polyspecific intravenous immunoglobulins
1Regional Red Cross Blood Transfusion Service SRC, Inselspital/University Hospital, Bern, Switzerland.
Journal of Clinical Apheresis
|January 1, 1997
Summary
Intravenous immunoglobulin (IVIG) treatment for sepsis is not indicated, failing to prevent fatalities. However, IVIG
Area of Science:
- Immunology
- Critical Care Medicine
- Pharmacology
Background:
- Current sepsis treatment guidelines do not recommend intravenous immunoglobulins (IVIG).
- Numerous placebo-controlled trials since 1985 have failed to demonstrate IVIG efficacy in preventing sepsis-related mortality.
- The traditional proposed mechanism of IVIG involves antibody-mediated opsonophagocytosis of pathogens.
Purpose of the Study:
- To explore the potential of IVIG's recently discovered immunomodulatory effects on cytokine networks for sepsis treatment.
- To identify potential improvements in IVIG-based sepsis study protocols and preparations.
Main Methods:
- Review of existing clinical studies and in vitro/in vivo research on IVIG and sepsis.
- Analysis of the role of cytokine dysregulation in sepsis progression.
- Discussion of novel strategies for IVIG application and preparation optimization.
Main Results:
- IVIG preparations demonstrate a significant impact on cytokine network homeostasis, potentially shifting it towards regulation.
- Cytokine storm and impaired clearance are critical in sepsis progression to septic shock.
- Emerging evidence suggests IVIG may modulate the cytokine network, offering a new therapeutic avenue.
Conclusions:
- The immunomodulatory effects of IVIG on cytokines warrant further investigation for sepsis treatment.
- Optimizing IVIG dosage, administration schedules, and patient selection may enhance therapeutic outcomes.
- Future research could involve modified IVIG preparations, including monoclonal antibodies or IgM-containing formulations, and improved patient stratification.